In the last year Provectus management has materially increased its rhetoric regarding the systemic effect of PV-10. As an example:
- In the last 12 months (May 2011 to May 2012), the company issued 26 PRs. In 9 of these PRs, the company and third parties mentioned the systemic effect a total of 22 times (14 and 8, respectively).
- Prior to that (May 2010 to May 2011), the company issued 20 PRs. In 4 of these PRs, the company and third parties mentioned the systemic effect 10 times (9 and 1, respectively).
What will the reaction be to the final MM Phase 2 data? Or, to PV-10 doing better in compassionate use? Or, to PV-10 doing better than expected in the MM P3 trial?
Awareness grows (a visual representation of blog readership):